

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number: 041673/2054		Application Number 10/032,952	
				Applicant: Tuszyński, Mark H.			
				Filing Date: 10/26/2001		Group Art Unit: 33	
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
grc	A1	01/21/92	5,082,670	Gage et al.	424	520	
	A2	06/25/96	5,529,774	Barba et al.	424	93, 21	
	A3	07/22/97	5,650,148	Gage et al.	424	93, 2	
	A4	11/04/97	5,683,695	Shen et al.	424	185, 1	
	A5	05/26/98	5,756,312	Weiner et al.	435	69, 3	
grc	A6	06/09/98	5,762,926	Gage et al.	424	93, 21	
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
grc	A7	06/28/90	WO 90/06757	PCT - WIPO			
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>							
Examiner Initials	Ref. No.	Title					
grc	A8	Armelin et al., "Pituitary extracts and steroid hormones in the control of 3T3 cell growth" <u>Proc. Natl. Acad. Sci.</u> (1973) <u>70</u> :2702-6.					
	A9	Banerji et al., "Expression of a beta-globin gene is enhanced by remote SV40 DNA sequences" <u>Cell</u> (1981) <u>27</u> :299-308.					
	A10	Benoist et al., "In vivo sequence requirements of the SV40 early promoter region" <u>Nature</u> (1981) <u>290</u> :304-10.					
	A11	Blesch et al., "Ex vivo gene therapy for Alzheimer's disease and spinal cord injury" <u>Clinical Neuroscience</u> (1996) <u>3</u> :268-274.					
	A12	Borsani et al., "cDNA sequence of human beta-NGF" <u>Nucleic Acids Res.</u> (1990) <u>18</u> :4020.					
	A13	Breathnach et al., "Organization and expression of eucaryotic split genes coding for proteins" <u>Ann. Rev. Biochem.</u> (1981) <u>50</u> :349-83.					
	A14	Chen et al., "Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA" <u>BioTechniques</u> (1988) <u>6</u> :632-8.					
	A15	Chen et al., "High-efficiency transformation of mammalian cells by plasmid DNA" <u>Mol. Cell. Biol.</u> (1987) <u>7</u> :2745-52.					
	A16	Chua et al., "Tumor necrosis factor-alpha induces mRNA for collagenase and TIMP in human skin fibroblasts" <u>Connect. Tissue Res.</u> (1990) <u>25</u> :161-170.					
grc	A17	Conner et al., "Distribution of NGF delivered into the rat CNS by either grafted NGF-secreting fibroblasts, intraparenchymal (IP) injections, or IP-infusions" <u>Society for Neuroscience</u> (1997) <u>23</u> :53 Abstract 29.5.					
.1 EXAMINER: <i>Shin-Lin Chen</i>				DATE CONSIDERED: <i>3-21-03</i>			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2054	Application Number: 10/032,952
		Applicant: Tuszynski, Mark H.	
		Filing Date: 10/26/2001	Group Art Unit: 163
OTHER DOCUMENTS <i>(including author, title, Date, Pertinent Pages, Etc.)</i>			
Initials	Ref. No.	Title	
<i>SL</i>	A18	Corden et al., "Promoter sequences of eukaryotic protein-coding genes." <u>Science</u> (1980) <u>209</u> :1406-14.	
	A19	DePamphilis et al., "Microinjecting DNA into mouse ova to study DNA replication and gene expression and to produce transgenic animals" <u>BioTechniques</u> (1988) <u>6</u> :662-80.	
	A20	de Wet et al., "The mRNAs for the pro-alpha 1(I) and pro-alpha 2(I) chains of type I procollagen are translated at the same rate in normal human fibroblasts and in fibroblasts from two variants of osteogenesis imperfecta with altered steady state ratios of the two mRNAs" <u>J. Biol. Chem.</u> (1983) <u>258</u> :14385-9.	
	A21	Elias et al., "Regulation of human lung fibroblast collagen production by recombinant interleukin-1, tumor necrosis factor, and interferon-gamma" <u>Ann. N.Y. Acad. Sci.</u> (1990) <u>580</u> :233-244.	
	A22	Felgner et al., "Cationic liposome mediated transfection" <u>Proc. West. Pharmacol. Soc.</u> (1989) <u>32</u> :115-21.	
	A23	Felgner et al., "Cationic liposome mediated transfection" <u>Focus</u> (1989) <u>11</u> :21-25.	
	A24	Felgner et al., "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :7413-7.	
	A25	Fraley et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids" <u>Trends Biochem. Sci.</u> (1981) <u>6</u> :77-80.	
	A26	Fromm et al., "Deletion mapping of DNA regions required for SV40 early region promoter function in vivo" <u>J. Mol. Appl. Genet.</u> (1982) <u>1</u> :457-81.	
	A27	Gruss et al., "Simian virus 40 tandem repeated sequences as an element of the early promoter" <u>Proc. Natl. Acad. Sci.</u> (1981) <u>78</u> :943-7.	
	A28	Hefti et al., "Nerve growth factor and Alzheimer's disease" <u>Ann. Neurol.</u> (1986) <u>20</u> :275-81.	
	A29	Higgins et al., "NGF receptor gene expression is decreased in the nucleus basalis in Alzheimer's disease" <u>Exp. Neurol.</u> (1989) <u>106</u> :222-36.	
	A30	Horellou et al., "Adenovirus-mediated gene transfer to the central nervous system for Parkinson's Disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :131-8.	
	A31	Jolly et al., "Elements in the long terminal repeat of murine retroviruses enhance stable transformation by thymidine kinase gene" <u>Nucleic Acids Res.</u> (1983) <u>11</u> :1855-1872.	
	A32	Kobayashi et al., "Morphometric study on the CH\$ of the nucleus basalis of Meynert in Alzheimer's disease" <u>Mol. Chem. Neuropathol.</u> (1991) <u>15</u> :193-206.	
	A33	Kojima, et al., "Adenovirus-Mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain," <u>Biochemical and Biophysical Research Communications</u> , <u>238</u> :569-573 (1997)	
	A34	Kordower et al., "The aged monkey basal forebrain: Rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor" <u>Proc. Natl. Acad. Sci.</u> (1994) <u>91</u> :10898-10902.	
<i>SL</i>	A35	Lehericy et al., "Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease" <u>J. Comp. Neurol.</u> (1993) <u>330</u> :15-31.	
EXAMINER: <i>Shin-Lin Chen</i>		DATE CONSIDERED: <i>3-21-03</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION APR 08 2002 Use several sheets if necessary)		Docket Number: 041673/2054	Application Number: 10/032,952
		Applicant: Tuszyński, Mark H.	
		Filing Date: 10/26/2001	Group Art Unit: 160

OTHER DOCUMENTS (including author, title, Date, Permanent Pages, Etc.)		
Examiner Initials	Ref. No.	Title
grc	A36	Levivier et al., "Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease" <u>The Jo. Of Neuroscience</u> (1995) <u>15</u> :7810-20.
	A37	Mannino et al., "Liposome mediated gene transfer" <u>Biotechniques</u> (1988) <u>6</u> :682-90.
	A38	Maxam et al., "Sequencing end-labeled DNA with base-specific chemical cleavages" <u>Methods in Enzymology</u> (1980) <u>65</u> :499-560.
	A39	McCutchan et al., "Enhancement of the infectivity of simian virus 40 deoxy ribonucleic acid with diethylaminoethyl-dextran" <u>J. Natl. Cancer Inst.</u> (1968) <u>41</u> :351-7.
	A40	Messing et al., "A system for shotgun DNA sequencing" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :309-21.
	A41	Mesulam et al., "Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey." <u>J. Comp. Neurol.</u> (1983) <u>214</u> :170-197.
	A42	Moreau et al., "The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants" <u>Nucleic Acids Res.</u> (1981) <u>9</u> :6047-6068.
	A43	Mufson et al., "Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: A quantitative analysis across subregions of the basal forebrain" <u>Exp. Neurol.</u> (1989) <u>105</u> :221-32.
	A44	Mufson et al., "Nerve growth factor receptor expressing human basal forebrain neurons: pathologic alterations in Alzheimer's and Parkinson's disease" <u>Prog. Clin. Biol. Res.</u> (1989) <u>317</u> :401-14.
	A45	Palmer et al., "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes" <u>Proc. Natl. Acad. Sci.</u> (1991) <u>88</u> :1330-4.
	A46	Potter et al., "Electroporation in biology: methods, applications, and instrumentation" <u>Anal. Biochem.</u> (1988) <u>174</u> :361-73.
	A47	Prockop et al., "Heritable diseases of collagen" <u>N. Eng. J. Med.</u> (1984) <u>311</u> :376-86.
	A48	Raymon et al., "Application of ex vivo gene therapy in the treatment of Parkinson's disease" <u>Experimental Neurobiology</u> (1997) <u>144</u> :82-91.
	A49	Roberts, et al., "Effects of NGF-Secreting Genetically Modified Cell Grafts on Cholinergic Neuronal Morphology and Cognition in Aged Primates," <u>Soc. For Neuroscience Abstracts</u> , <u>21</u> (2):613.8 (1995)
	A50	Rossi et al., "Identification of a cell-specific transcriptional enhancer in the first intron of the mouse alpha 2 (type I) collagen gene" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :5590-4.
	A51	Schmidt et al., "Regulation of a collagen promoter by the product of viral mos oncogene" <u>Nature</u> (1985) <u>314</u> :286-9.
	A52	Seliger et al., "Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription" <u>J. Virology</u> (1988) <u>62</u> :619-21.
grc	A53	Seliger et al., "Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level" <u>J. Immunol.</u> (1988) <u>141</u> :2138-44.

EXAMINER:	shin-Lin Chen	DATE CONSIDERED:	3-21-03
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 041673/2054	Application Number: 10/032,952
		Applicant: Tuszyński, Mark H.	
		Filing Date: 10/26/2001	Group Art Unit: 163
OTHER DOCUMENTS <i>(including author, title, Date, Page Number, Etc.)</i>			
Initials	Ref. No.	Title	
ML	A54	Shvaloff et al., "Lines of therapeutic research in Alzheimer's disease" <u>Psychopharmacology Bulletin</u> (1996) <u>32</u> :343-52..	
	A55	Smith et al., "Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy" <u>Proc. Natl. Acad. Sci.</u> (1999) <u>96</u> :10893-8.	
	A56	Smith et al., "Characterization of collagen synthesized by normal and chemically transformed rat liver epithelial cell lines" <u>Biochem.</u> (1980) <u>19</u> :1820-5.	
	A57	Toneguzzo et al., "Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells" <u>Molec. Cell. Biol.</u> (1986) <u>6</u> :703-6.	
	A58	Tuszyński et al., "Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration" <u>Gene Therapy</u> (1996) <u>3</u> :305-14.	
	A59	Tuszyński et al., "Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain" <u>Ann. Neurol.</u> (1991) <u>30</u> :625-36.	
	A60	Tuszyński et al., "Somatic gene therapy for nervous system disease" <u>Ciba Foundation Symposium 196, Growth factors as drugs for neurological and sensory disorders</u> (1996) <u>196</u> :85-97.	
	A61	Tuszyński et al., "Targeted Intraparenchymal Delivery of Human NGF by Gene Transfer to the Primate Basal Forebrain for 3 Months Does Not Accelerate β -Amyloid Plaque Deposition," <u>Experimental Neurology</u> (1998) Article No. EN986956 1-10.	
	A62	Tuszyński et al., "The chronically injured spinal cord exhibits responsiveness to NGF delivered locally by gene therapy" <u>Society for Neuroscience</u> (1995) <u>21</u> :1562 Abstract 613.3.	
	A63	Ullrich et al., "Human beta-nerve growth factor gene sequence highly homologous to that of a mouse" <u>Nature</u> (1983) <u>303</u> :821-5.	
	A64	Wolff et al., "Expression of retrovirally transduced genes in primary cultures of rat hepatocytes" <u>Proc. Natl. Acad. Sci.</u> (1987) <u>84</u> :3344-8.	
	A65	Yang, et al., "Gene Therapy for Central Nervous System Injury: The Use of Cationic Liposomes: An Invited Review," <u>Journal of Neurotrauma</u> , <u>14</u> (5):281-297 (1997)	
ML	A66	Zlokovic, et al., "Cellular and Molecular Neurosurgery: Pathways From Concept to Reality – Part II: Vector Systems and Delivery Methodologies for Gene Therapy of The Central Nervous System," <u>Neurosurgery</u> , <u>40</u> (4):805-813 (1997)	
EXAMINER: <i>Shin-Lin Chen</i>		DATE CONSIDERED: <i>3-21-03</i>	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			